FDA OKs Roche doublet therapy for first-line liver cancer

The FDA approves the combination of Roche’s (OTCQX:RHHBY -1.5%) Tecentriq (atezolizumab) and Avastin (bevacizumab) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

The nod is the ninth for Tecentriq and 13th for Avastin in the U.S.

https://seekingalpha.com/news/3578757-fda-oks-roche-doublet-therapy-for-first-line-liver-cancer